Description: ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.
Home Page: www.reneuron.com
RENE Technical Analysis
Pencoed Business Park
Pencoed,
CF35 5HY
United Kingdom
Phone:
44 20 3819 8400
Officers
| Name | Title |
|---|---|
| Ms. Catherine Isted A.C.M.A. | CEO & Exec. Director |
| Dr. John David Sinden B.A., BA, M.A., MA, Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. John Michael Hawkins A.C.A. | CFO & Director |
| Ms. Suzanne Hancock | Chief Operations Officer |
| Dr. Randolph Corteling Ph.D. | Chief Scientific Officer |
| Mr. Simon Dew | Chief Bus. Officer |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9481 |
| Price-to-Sales TTM: | 7.901 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 34 |